Transcatheter Embolization and Occlusion Devices – Market Insights – Europe

The European TEO device market is set for modest growth over the forecast period, driven by the rising adoption of minimally invasive procedures. This trend is further bolstered by the introduction of innovative new devices, which are gaining traction due to positive outcomes demonstrated in clinical trials. As healthcare providers continue to embrace these advancements, their growing confidence in these novel devices is expected to lead to a steady increase in market demand throughout the forecast period.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for TEO devices in Europe from 2019 through 2033.

Companies are launching new devices as well as improved versions of existing products to remain competitive in the expanding market.

Which new devices are anticipated to enter the European market within the forecast period, and when are they expected to be launched?

Which strategies are competitors adopting to gain a competitive edge over other competitors in the TEO device market?

How has the competitive landscape changed with the emergence of new competitors and products?

DEBs and radioembolization spheres are seeing increasing adoption.

How will the market growth vary across different embolization particle categories?

What is the adoption outlook for different embolization devices, and what factors will affect the penetration of these technologies over the forecast period?

What impact will clinical guidelines and clinical trials have on the adoption of DEBs and radioembolization spheres?

How are radioembolization spheres being adopted by physicians in the European market?

Emergence of evidence supporting use of embolization devices in the treatment of chronic subdural hematoma will support TEO procedure volume growth.

Which embolization devices will see the strongest adoption in the treatment of chronic subdural hematoma?

How will the uptake of embolization procedures in the treatment of chronic subdural hematoma vary across Europe?